Advertisement

Kiniksa Pharmaceuticals International, plc KNSA

Set alert

Price alert · KNSA

All alert types
92.24 USD -5.32 -5.45%

At close · Oct 30

92.15 -0.09 -0.10%

After hours · Oct 30, 4:56 PM ET

Bid
92.10 × 2
Ask
92.24 × 2
91.25 Day range 98.48
37.01 52-week range 97.56
YTD
+123.61%
1 year
+147.36%
Open
97.60
Prev close
97.56
Mkt cap
7.25B
Vol
1.32M
Avg vol
620.55K
EPS
1.32
P/E
69.88
Div yield
0.00%
More statistics
Low
91.25
High
98.48
Forward P/E
42.80
Beta
0.04
Short ratio
6.53
Inst. own
101.26%
Dividend
0.00
Ex-div date
Earnings
Feb 23, 2027
50-d avg
78.88
200-d avg
59.94
1y target
103.63

5D chart

Chart tools
Interval

Events in this range
  • Oct 27, 2026Earnings: 0.56; estimate 0.371; surprise 50.94%
  • Oct 28, 2026Rating: Wells Fargo · Overweight → Overweight
  • Oct 28, 2026Rating: Wedbush · Outperform → Outperform
  • Oct 28, 2026Rating: Goldman Sachs · Buy → Buy
Signals (109)
NameTimeAgo
RSI: OversoldOct 30, 10:10 AM1 day ago
SMA: BearishOct 30, 9:50 AM1 day ago
SMA: BearishOct 30, 9:50 AM1 day ago
MACD: Sell SignalOct 30, 9:50 AM1 day ago
SMA: BullishOct 30, 9:35 AM1 day ago
SMA: BullishOct 30, 9:35 AM1 day ago
MACD: Buy SignalOct 30, 9:35 AM1 day ago
SMA: BearishOct 30, 9:30 AM1 day ago
SMA: BearishOct 30, 9:30 AM1 day ago
MACD: Sell SignalOct 30, 9:30 AM1 day ago
SMA: BullishOct 29, 3:30 PM2 days ago
MACD: Buy SignalOct 29, 3:30 PM2 days ago
SMA: BullishOct 29, 3:25 PM2 days ago
SMA: BearishOct 29, 3:20 PM2 days ago
SMA: BearishOct 29, 3:20 PM2 days ago
MACD: Sell SignalOct 29, 3:20 PM2 days ago
MACD: Buy SignalOct 29, 3:15 PM2 days ago
SMA: BullishOct 29, 3:10 PM2 days ago
SMA: BullishOct 29, 3:05 PM2 days ago
SMA: BearishOct 29, 2:25 PM2 days ago
SMA: BearishOct 29, 2:25 PM2 days ago
SMA: BullishOct 29, 2:20 PM2 days ago
SMA: BullishOct 29, 2:20 PM2 days ago
SMA: BearishOct 29, 2:15 PM2 days ago
SMA: BearishOct 29, 2:15 PM2 days ago
SMA: BullishOct 29, 2:05 PM2 days ago
SMA: BullishOct 29, 1:55 PM2 days ago
SMA: BearishOct 29, 1:50 PM2 days ago
SMA: BearishOct 29, 1:50 PM2 days ago
SMA: BullishOct 29, 1:45 PM2 days ago
SMA: BullishOct 29, 1:30 PM2 days ago
SMA: BearishOct 29, 1:20 PM2 days ago
SMA: BearishOct 29, 12:50 PM2 days ago
SMA: BullishOct 29, 12:30 PM2 days ago
MACD: Sell SignalOct 29, 11:55 AM2 days ago
SMA: BearishOct 29, 11:50 AM2 days ago
MACD: Buy SignalOct 29, 11:10 AM2 days ago
RSI: OverboughtOct 29, 11:10 AM2 days ago
SMA: BullishOct 29, 11:00 AM2 days ago
MACD: Sell SignalOct 29, 10:20 AM2 days ago
SMA: BearishOct 29, 10:15 AM2 days ago
RSI: OverboughtOct 29, 9:45 AM2 days ago
MACD: Buy SignalOct 29, 9:40 AM2 days ago
SMA: BullishOct 28, 3:20 PM3 days ago
SMA: BearishOct 28, 2:55 PM3 days ago
MACD: Sell SignalOct 28, 2:55 PM3 days ago
SMA: BullishOct 28, 1:50 PM3 days ago
MACD: Buy SignalOct 28, 1:50 PM3 days ago
RSI: OverboughtOct 28, 1:50 PM3 days ago
SMA: BearishOct 28, 1:45 PM3 days ago
MACD: Sell SignalOct 28, 1:45 PM3 days ago
SMA: BullishOct 28, 1:35 PM3 days ago
SMA: BearishOct 28, 1:25 PM3 days ago
RSI: OverboughtOct 28, 12:40 PM3 days ago
SMA: BullishOct 28, 11:35 AM3 days ago
SMA: BearishOct 28, 11:30 AM3 days ago
SMA: BullishOct 28, 11:25 AM3 days ago
SMA: BearishOct 28, 11:20 AM3 days ago
SMA: BullishOct 28, 10:50 AM3 days ago
MACD: Buy SignalOct 28, 10:50 AM3 days ago
SMA: BullishOct 28, 10:35 AM3 days ago
SMA: BearishOct 28, 10:00 AM3 days ago
SMA: BearishOct 28, 9:55 AM3 days ago
SMA: BullishOct 28, 9:50 AM3 days ago
SMA: BearishOct 27, 3:50 PM4 days ago
SMA: BearishOct 27, 3:45 PM4 days ago
MACD: Sell SignalOct 27, 3:45 PM4 days ago
MACD: Buy SignalOct 27, 3:10 PM4 days ago
SMA: BullishOct 27, 3:00 PM4 days ago
SMA: BearishOct 27, 2:55 PM4 days ago
SMA: BullishOct 27, 2:35 PM4 days ago
SMA: BullishOct 27, 2:25 PM4 days ago
SMA: BearishOct 27, 2:10 PM4 days ago
SMA: BullishOct 27, 2:05 PM4 days ago
SMA: BearishOct 27, 2:00 PM4 days ago
SMA: BullishOct 27, 1:55 PM4 days ago
SMA: BearishOct 27, 1:50 PM4 days ago
SMA: BearishOct 27, 1:35 PM4 days ago
SMA: BullishOct 27, 1:20 PM4 days ago
SMA: BearishOct 27, 1:15 PM4 days ago
RSI: OverboughtOct 27, 1:00 PM4 days ago
RSI: OverboughtOct 27, 12:50 PM4 days ago
RSI: OverboughtOct 27, 12:35 PM4 days ago
SMA: BullishOct 27, 11:35 AM4 days ago
SMA: BearishOct 27, 11:30 AM4 days ago
MACD: Sell SignalOct 27, 10:35 AM4 days ago
SMA: BullishOct 27, 10:20 AM4 days ago
SMA: BearishOct 27, 10:15 AM4 days ago
RSI: OverboughtOct 27, 9:30 AM4 days ago
RSI: OverboughtOct 26, 3:45 PM5 days ago
SMA: BullishOct 26, 3:30 PM5 days ago
SMA: BearishOct 26, 3:25 PM5 days ago
SMA: BullishOct 26, 3:00 PM5 days ago
SMA: BullishOct 26, 3:00 PM5 days ago
SMA: BearishOct 26, 2:40 PM5 days ago
SMA: BearishOct 26, 2:35 PM5 days ago
SMA: BullishOct 26, 2:30 PM5 days ago
SMA: BullishOct 26, 2:30 PM5 days ago
SMA: BearishOct 26, 2:20 PM5 days ago
SMA: BearishOct 26, 2:15 PM5 days ago
SMA: BullishOct 26, 2:00 PM5 days ago
SMA: BullishOct 26, 2:00 PM5 days ago
SMA: BearishOct 26, 1:40 PM5 days ago
SMA: BullishOct 26, 1:05 PM5 days ago
MACD: Buy SignalOct 26, 1:05 PM5 days ago
MACD: Sell SignalOct 26, 12:30 PM5 days ago
RSI: OversoldOct 26, 12:30 PM5 days ago
SMA: BearishOct 26, 11:30 AM5 days ago
SMA: BullishOct 26, 11:15 AM5 days ago

Key statistics

Market cap
7.25B
Enterprise value
7.10B
Trailing P/E
69.88
Forward P/E
42.80
PEG ratio
0.00
Price / sales
7.66
Price / book
10.19
EPS (TTM)
1.32
Beta
0.04
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
11.58%
Revenue (TTM)
945.96M
Revenue growth
58.10%
Free cash flow
135.87M
Total cash
568.76M
Total debt
7.88M
Return on equity
17.59%
Shares outstanding
48.84M
Short % of float
9.31%
50-day average
78.88
200-day average
59.94

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 103.63 +12.3% upside
Target (low)
87.00
Target (mean)
103.63
Target (high)
134.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy7
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Feb 23, 2027

Expected Feb 23, 2027. Consensus EPS estimate 0.39.

Earnings history

Financials — quick view

All financials
KNSA Revenue — quarterly 285.97M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
KNSA Net income — quarterly 47.34M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
KNSA EPS — quarterly 0.61
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

KNSA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.25———
Oct 27, 2026Sep 30, 20260.3710.56+0.19+50.94%
Jul 28, 2026Jun 30, 20260.29950.300.00+0.17%
Apr 28, 2026Mar 31, 20260.180.27+0.09+50.00%
Feb 24, 2026Dec 31, 20250.290.17-0.12-41.38%
Oct 28, 2025Sep 30, 20250.330.23-0.10-30.30%

Upgrades / downgrades

KNSA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 28, 2026Goldman SachsmainBuyBuy
Oct 28, 2026WedbushmainOutperformOutperform
Oct 28, 2026Wells FargomainOverweightOverweight
Jul 30, 2026Goldman SachsmainBuyBuy
Jul 29, 2026JP MorganmainOverweightOverweight
Jul 29, 2026Canaccord GenuitymainBuyBuy

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United Kingdom
Website
kiniksa.com

News

Your note

Sign in to keep a note on KNSA — it syncs with the Stock Master app.

Insider holders

KNSA insider holders
InsiderRelationLatest transactionDateShares held
BAKER BROS ADVISORS L.P.UnknownStock Award(Grant)May 28, 20260
BAKER BROTHERS LIFE SCIENCES, L.P.DirectorStock Award(Grant)Jun 2, 20250
LEVY RICHARD SDirectorConversion of Exercise of derivative securityJul 30, 202622,359
MALLEY THOMAS ROBERTDirectorConversion of Exercise of derivative securityMay 28, 202687,312
MEGNA MICHAEL ROfficerSaleSep 2, 202629,062
MOAT ROSSChief Operating OfficerConversion of Exercise of derivative securityAug 31, 202616,307

Institution ownership

KNSA institution ownership
Holder% heldSharesValueReported
FMR, LLC17.30%6,971,361643.04MJun 29, 2026
Rubric Capital Management LP9.92%3,999,800368.94MJun 29, 2026
Baker Bros. Advisors, LP7.03%2,834,643261.47MJun 29, 2026
Blackrock Inc.6.80%2,739,615252.70MJun 29, 2026
Tang Capital Management, LLC5.61%2,259,889208.45MJun 29, 2026
Vanguard Portfolio Management LLC4.74%1,911,335176.30MJun 29, 2026

Fund ownership

KNSA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.27%1,318,452121.61MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.93%1,180,466108.89MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio2.41%970,00089.47MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.37%954,71988.06MJun 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 1.68%676,14662.37MAug 30, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio1.58%637,60058.81MAug 30, 2026
Advertisement